Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials.
Biobanks
Cancer
Clinical trials
FFPE blocks
NCTN
Oncology
Pathology
Policy
Journal
American journal of clinical pathology
ISSN: 1943-7722
Titre abrégé: Am J Clin Pathol
Pays: England
ID NLM: 0370470
Informations de publication
Date de publication:
02 01 2020
02 01 2020
Historique:
pubmed:
16
10
2019
medline:
23
4
2020
entrez:
16
10
2019
Statut:
ppublish
Résumé
The National Cancer Institute (NCI) National Clinical Trials Network performs phase II and III clinical trials, which increasingly rely on the submission of diagnostic formalin-fixed, paraffin-embedded tissue blocks for biomarker assessment. Simultaneously, advances in precision oncology require that clinical centers maintain diagnostic specimens for ancillary, standard-of-care diagnostics. This has caused tissue blocks to become a limited resource for advancing the NCI clinical trial enterprise and the practice of modern molecular pathology. The NCI convened a 1-day workshop of multidisciplined experts to discuss barriers and strategic solutions to facilitate diagnostic block submission for clinical trial science, from the perspective of patient advocates, legal experts, pathologists, and clinical oncologists. The expert views and opinions were carefully noted and reported. Recommendations were proposed to reduce institutional barriers and to assist organizations in developing clear policies regarding diagnostic block submission for clinical trials.
Identifiants
pubmed: 31613330
pii: 5587750
doi: 10.1093/ajcp/aqz141
pmc: PMC7169836
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
149-155Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233339
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© American Society for Clinical Pathology, 2019.
Références
Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):667-72
pubmed: 15066936
MLO Med Lab Obs. 2004 Jun;36(6):37
pubmed: 15242181
J Histochem Cytochem. 2011 Dec;59(12):1113-21
pubmed: 22147608
Arch Pathol Lab Med. 2008 Dec;132(12):1929-35
pubmed: 19061293
N Engl J Med. 2006 Oct 12;355(15):1517-9
pubmed: 17035644
Am J Pathol. 2004 Jan;164(1):35-42
pubmed: 14695316
PLoS Med. 2012;9(5):e1001216
pubmed: 22675273
J Clin Pathol. 2008 Jan;61(1):79-83
pubmed: 17412873
J Natl Cancer Inst. 1996 Aug 7;88(15):1054-9
pubmed: 8683636
Clin Transl Med. 2014 Mar 17;3(1):4
pubmed: 24636624
Am J Pathol. 2001 Feb;158(2):419-29
pubmed: 11159180
Clin Lab Med. 2005 Sep;25(3):487-98
pubmed: 16129189
Arch Pathol Lab Med. 2011 Jul;135(7):870-3
pubmed: 21732776
Nat Rev Genet. 2002 Feb;3(2):145-8
pubmed: 11836508
J Clin Pathol. 2002 Aug;55(8):575-6
pubmed: 12147648
Mod Pathol. 2004 Nov;17(11):1414-20
pubmed: 15205686
Lab Invest. 2000 Dec;80(12):1943-9
pubmed: 11140706